


dw/B 1652



Docket No.: 0660-0155-0 DIV

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

ATTORNEYS AT LAW

RE: Application Serial No.: 09/357,375

Applicants: Michel ARTHUR, et al.

Filing Date: July 20, 1999

For: POLYPEPTIDES IMPLICATED IN THE  
EXPRESSION OF RESISTANCE TO  
GLYCOPEPTIDES, IN PARTICULAR IN GRAM-  
POSITIVE BACTERIA, NUCLEOTIDE SEQUENCE  
CODING FOR THESE POLYPEPTIDES AND USE  
FOR DIAGNOSIS

Group Art Unit: 1652

Examiner: HUTSON

SIR:

Attached hereto for filing are the following papers:

**AMENDMENT**

Our check in the amount of \_\_\_\_\_ is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Customer Number

**22850**


(703) 413-3000 (phone)  
(703) 413-2220 (fax)

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Daniel J. Pereira, Ph.D.

Registration No. 45,518



DOCKET NO: 0660-0155-0 DIV

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :  
MICHEL ARTHUR, ET AL. : EXAMINER: HUTSON  
SERIAL NO: 09/357,375 :  
FILED: JULY 20, 1999 : GROUP ART UNIT: 1652  
FOR: POLYPEPTIDES IMPLICATED IN :  
THE EXPRESSION OF RESISTANCE TO  
GLYCOPEPTIDES, IN PARTICULAR IN  
GRAM-POSITIVE BACTERIA,  
NUCLEOTIDE SEQUENCE CODING FOR  
THESE POLYPEPTIDES AND USE FOR  
DIAGNOSIS

AMENDMENT

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Office Communication dated January 10, 2005, please amend the  
above-identified application as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Remarks** begin on page 5 of this paper.